Driving Menarini's Future With Decisive Steps

CEO Outlines Strategy And Focus On Oncology

27 Sep 2021

Two years into her tenure as the head of Menarini, Elcin Barker Ergun has already inked two major cancer deals with the acquisition of Stemline and a key licensing pact with Radius Health. The future for the Italian group is bright, she explained to Scrip in an exclusive interview.

Elcin Barker 1200 — Leading from the front: Elcin Barker Ergun • Source: Menarini

As the head of one of the oldest pharmaceutical companies in the world, founded 135 years ago, Menarini Group's CEO Elcin Barker Ergun is proud of the Italian group's heritage while focusing on spearheading its future and creating a firm that will be known not just for commercial excellence but for R&D innovation, specifically in the field of cancer.

It is two years since Barker Ergun took over as CEO of Menarini, joining from Merck KGaA's healthcare unit. Her appointment caught the eye not only because she became...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

28 May 2025

• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

27 May 2025

• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Pharma Women’s Workforce In India: Weak Start, Promotions, C-Suite Drop Off

26 May 2025

• By Anju Ghangurde

McKinsey senior partner Vivek Pandit talks to Scrip about some of the intricacies underlying the key findings of a study on pharma’s workforce gender gap in India. Women’s representation starts low at entry level, peaks at senior manager positions and falls off again for C-suite roles, this found.